Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Eli Lilly said sales of its blockbuster diabetes treatment, Trulicity, rose 20% from last year to $1.23 billion, but overall revenues missed analysts' forecasts. Eli Lilly & Co. (LLY) posted ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Doctors prescribe Lilly's Mounjaro and Zepbound to help patients manage their weight, and the results have been fantastic.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Eli Lilly (NYSE:LLY) shares traded in the red on Wednesday, breaking a streak of six straight days of gains. Stock closed ...
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
Eli Lilly reported first-quarter adjusted profit that topped Wall Street's expectations. The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and ...
Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career ...
Alphabet has announced who its new chief financial officer (CFO) will be, revealing today that it has hired pharmaceutical ...
, opens new tab said on Thursday its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...